




Unstimulated hPBMCs (round, circular)



Stimulated hPBMCs (round, circular aggregates)



Co-cultured hMSC (long, flat) and hPBMCs (round, circular & some aggregates)

**FIGURE 1**



MLPSC A
MLPSC B
MLPSC C
MLPSC D
MLPSC E
MLPSC F
0
20
40
60
80
100
Inhibition of T-cell proliferation (%, IL2R assay)

**FIGURE 2**



MLPSC A
MLPSC B
MLPSC C
MLPSC D
MLPSC E
MLPSC F
0
100
200
300
400
500
TNFRI (Product Dose: pg/ml)

**FIGURE 3**



Product-Limit Survival Estimates
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
+ Censored
Logrank p=0.0068
0
20
40
60
80
100
Survival Days From First Study Treatment
Response:
Responders
Non-Responders

**FIGURE 4**



Culture Expanded Mesenchymal Stromal Cells (ce-MSC) Manufacturing [Drug Substance to Drug Product Continuous Process]
Key Materials
Unit Operations
Analytical Methods
Active Substance
Finished Product
Growth Medium Cell Factory
Thaw DCB cryobag (Passage 3)
Cell Count Viability
Change media 3 times
HBSS rTrypsin Stop Solution Growth Media Cell Factories
Passage 4 (P3 → P4) at day 12-16 Seed 8 cell factories
Cell Count Viability
Change media 2 times
HBSS rTrypsin Stop Solution Growth Media Cell Factories
Passage 5 (P4 → P5) at day 12-16 Seed 48 cell factories
Cell Count Viability
Change media 2 times
HBSS rTrypsin Stop Solution Plasmalyte-A 25% HSA
Final Harvest of P5 cells at day 9-12 by TFF
Cell Count Viability Spent Media
Plasmalyte-A 25%HSA
2XDP Formulation
Mycoplasma Sterility
Plasmalyte-A 25%HSA DMSO
1XDP Formulation
Cryo Reserve Formulation Matrix
6ml Aseptic Tech Vials Dual Screen Filter
Filtration, Filling Visual Inspection and Labeling
Visual Inspection
Cryopreservation and Storage of DP
Cell Count
Viability
Potency
Endotoxin
FACS
Sterility
Appearance
Residuals

**FIGURE 5**





FIGURE 6



PBMC IL-2Rα (% inhibition)
% Inhibition
100
90
80
70
60
50
40
30
20
10
0
1
2
3
4
5
6
7
8
9
10
Lot

**FIGURE 7**